MYO9A

Across TCGA pan-cancer cohorts, MYO9A RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated MYO9A data layer compared with 10 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MYO9A RNA is associated with better overall survival. In most high-consensus cancer types, elevated MYO9A expression acts as an unfavorable survival marker, although some lineages such as KIRC and ESCA show a favorable association.

KIRC, ACC, and BLCA are the cancer types where MYO9A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.729	0.545	<.001	152	view →
ACC	DFS	Median	All	0.384	0.773	<.001	62	view →
BLCA	DFS	Quartile	All	0.187	0.633	.006	38	view →
UVM	DFS	Median	III,IV	0.267	0.796	.002	28	view →
ESCA	OS	Tertile	III,IV	0.711	0.320	.003	28	view →
UCS	DFS	Tertile	IV	0.942	0.403	.024	24	view →
PAAD	DFS	Median	All	0.250	0.476	.003	21	view →
LUSC	DFS	Median	IV	0.134	0.827	.014	18	view →
GBM	OS	Tertile	All	0.589	0.274	.009	18	view →
UCEC	OS	Tertile	II,III,IV	0.693	0.855	.010	16	view →
HNSC	OS	Median	IV	0.799	0.660	.018	14	view →
KIRP	DFS	Tertile	All	1.000	0.772	.007	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

MYO9A–KIRC (OS)

Open the KIRC breakdown →